Oct 15, 2014 by Brian Orelli, PhDFDA Sends Mixed Message On Safety of Pfizer inc.'s ChantixThe smoking cessation product might not cause neuropsychiatric events, but the FDA wants more data.
Oct 10, 2014 by Brian Orelli, PhDGilead Sciences Inc. Gets First Hepatitis C Cocktail Drug ApprovedNow the question is how much is Gilead Sciences going to make off Harvoni.
Oct 10, 2014 by Brian Orelli, PhDAmgen, Inc. Gives AbbVie Inc the Highest Form of FlatteryAmgen is developing a biosimilar of AbbVie's Humira.
Oct 9, 2014 by Brian Orelli, PhDBristol-Myers Co Regroups; Hepatitis C Fight With Gilead Sciences Not OverBristol-Myers Squibb pulls its FDA application for daclatasvir and asunaprevir. Here are two possible reasons why.
Oct 7, 2014 by Brian Orelli, PhDShould Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?Esperion Therapeutics might be small, but it could pack a mighty punch.
Oct 4, 2014 by Brian Orelli, PhDGilead Sciences, Inc. Got 2 Drugs Approved, and Didn't Bother to Tell AnyoneGilead Science's Tybost and Vitekta are already part of its approved quad pill Stribild.
Oct 4, 2014 by Brian Orelli, PhDThe Next Blue-Chip Stocks: Biogen IdecBiogen Idec could hit blue chip status, but it's going to take a few years.
Oct 4, 2014 by Brian Orelli, PhDDividend Aristocrats: Time to Buy Johnson & JohnsonDividend increases make Johnson & Johnson a buy anytime.
Sep 30, 2014 by Brian Orelli, PhDBig News for These 5 Stocks From ESMOBut smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.
Sep 27, 2014 by Brian Orelli, PhDThese Companies Are Saving Money and Sticking You With a Tax BillMoving abroad results in lower tax bills for companies, but investors often have to pay capital-gains taxes when their transactions go through.
Sep 25, 2014 by Brian Orelli, PhDThis Switch Could Make Gilead Sciences, Inc. Stock BillionsSwapping HIV treatments Viread and TAF will extend Gilead Sciences patent protection.
Sep 23, 2014 by Brian Orelli, PhDRegeneron Pharmaceuticals Inc Stock Racks Up Another WinBayer and Regeneron Pharmaceuticals get three Eylea approvals in as many months.
Sep 22, 2014 by Brian Orelli, PhDSurprising Silver Lining for Gilead Sciences, inc. StockThere's a silver lining in CVS's data on Gilead Sciences' Sovaldi.
Sep 19, 2014 by Brian Orelli, PhD3 Biotechs Investors Should WatchThe healthcare version of Where the Money Is.
Sep 19, 2014 by Brian Orelli, PhD5 Things Gilead Sciences, Inc. Management Wants You to KnowAnalysis of comments from Gilead Sciences' president and COO.
Sep 17, 2014 by Brian Orelli, PhD5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to KnowHighlights from Arena Pharmaceuticals' conference call with investors.
Sep 11, 2014 by Brian Orelli, PhDFDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity DrugOrexigen and Takeda's Contrave has the right balance of efficacy and safety.
Sep 10, 2014 by Brian Orelli, PhDMedivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Cancer Drug Medivation and Astellas get expanded FDA approval for Xtandi with a label that looks better than Johnson & Johnson's Zytiga.
Sep 9, 2014 by Brian Orelli, PhD3 Reasons MannKind Corporation's Stock Could FallMannKind is dependent on the launch of inhaled insulin Afrezza and its marketing partner Sanofi.
Sep 8, 2014 by Brian Orelli, PhDEbola Outbreak Strikes Africa: How We're Fighting BackMultiple drugs and vaccines are in development.
